Johnson & Johnson (JNJ) Stake Decreased by Acropolis Investment Management LLC
Acropolis Investment Management LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,705 shares of the company’s stock after selling 1,142 shares during the quarter. Johnson & Johnson makes up about 0.6% of Acropolis Investment Management LLC’s investment portfolio, making the stock its 17th biggest holding. Acropolis Investment Management LLC’s holdings in Johnson & Johnson were worth $3,665,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Lenox Wealth Advisors Inc. lifted its stake in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after buying an additional 841 shares during the last quarter. Ullmann Financial Group Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth about $186,000. Taylor Wealth Management Partners lifted its stake in shares of Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after buying an additional 250 shares during the last quarter. Finally, Foundation Resource Management Inc. bought a new position in Johnson & Johnson during the first quarter worth about $204,000. Institutional investors and hedge funds own 65.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first published by Marea Informative and is the property of of Marea Informative. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at http://www.mareainformativa.com/johnson-johnson-jnj-shares-sold-by-acropolis-investment-management-llc/117220/.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.29% during mid-day trading on Friday, reaching $136.43. The company had a trading volume of 4,106,625 shares. The firm has a 50-day moving average price of $132.54 and a 200-day moving average price of $130.20. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.52. The stock has a market capitalization of $366.18 billion, a price-to-earnings ratio of 23.08 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter last year, the business posted $1.74 earnings per share. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current year.
A number of research firms recently commented on JNJ. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $129.62 price target on the stock. in a research report on Friday. Jefferies Group LLC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the company from $145.00 to $157.00 in a report on Wednesday. Wells Fargo & Company upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and raised their price target for the company from $140.00 to $149.00 in a research note on Monday, October 9th. Cowen and Company set a $147.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, October 6th. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $135.98.
In related news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.